By selecting the Yes option, leaving Amgen.nl option you understand that you are leaving the corporate page of Amgen nl and that you will be redirected to another Internet site belonging to third parties, for whose content or opinions Amgen nl is not responsible and makes no representations regarding such content or its accuracy. By selecting this option and accessing linked third party sites, you understand that you do so at your own risk.
The website to which you will be redirected may be designed exclusively for residents of a particular country or countries, as advertised on that website. As a consequence, the website to which you will be directed may contain information on pharmaceutical products or indications that are not approved in nl. If You reside in a country other than the one to which such website is directed, please contact your local Amgen affiliate for the correct information on products in your country of residence.
Our story began with the simple idea that emerging genetics research could lead to exciting opportunities in medicine if we connected the world’s smartest scientists with the right resources.
In 1983 came one of the first big Amgen discoveries. After working tirelessly for over two years combining through 1.5 million fragments of the human genome, a team led by a young Amgen scientist, Fu-Kuen Lin, successfully isolated and cloned the erythropoietin gene responsible for the stimulation of red blood cell production. This discovery, approved by the FDA in 1989, changed medicine and the lives of millions of people with kidney failure. It remains one of the most successful medical advances ever made. Since then, Amgen grew to be one of the largest independent biotech companies in the world.
Since Amgen’s founding in 1980 as one of the first biotech start-ups of the biotech revolution, we have grown into one of the largest independent biotech companies in the world.
Amgen helped pioneer the science of using living cells to make biologic medicines, and we helped invent the processes and equipment that built the global biotechnology industry into a leading source of medical therapies for patients. Our world-class scientists lead the field in discovering novel ways to treat serious diseases, and some of world’s greatest scientific advances are happening now inside Amgen.
Established in 1995 Amgen Breda has grown into a multifunctional site with integrated capabilities, +900 employees covering over 40 different nationalities that support Amgen’s mission ‘serving patients’. Since the start of the production and distribution in 1996, Amgen Breda has been growing. Currently our production facility assembles, labels and packs around 40 million units annually. While our distribution center is responsible for final shipments around the globe. Curious who we are today?
In Amgen Breda we produce and distribute medicines throughout Europe and a growing number of countries in other parts of the world. But we do much more. Here is an impression of what happens inside Amgen Breda!
Welcome to Amgen a multifunctional site that is integrated capabilities to support engines global expansion. Annually the multi-language customer success department handles more than 450,000 orders from around the world; the planning department makes an optimal efficient production schedule ensuring that the patients receive their medicines on time. Patients and health care professionals need to be able to read the information about the product in their local language a dedicated artwork department is equipped to design artwork in multiple languages carefully checked for quality. All components are received in the internal distribution center before release to production the components are checked by the quality department. Based on the production schedule all components are prepared for final packaging. The site's agile production facility assembles labels and packs around 25 million units annually fully automated for large production orders semi automated and manual for smaller production orders. All according to country specific requirements.
Returning to our distribution center the products are now ready for final shipment around the globe. After a final quality check is done Amgen products are released ot he market. A global supply chain organization reaching Europe and Intercontinental ensure the supply of Amgen products to the world. The Breda site supports Amgen's clinical trials the clinical operations department is responsible for setting up customized supply chain solutions for all Amgen studies conducted in 57 countries across the globe. Clinical customer service ensures timely delivery to clinical sites and 22 depot’s across the globe closely partnering with the Breda distribution team. The international operations Information Systems organization and the finance and global business services organization provides supporting services to Amgen entities in Europe and beyond.
Breda is also home to the Netherlands affiliate. Main activities are focused on clinical research and servicing patients in the Dutch market. Clinical research is vital for Amgen's mission to serve patients the Netherlands is a key country for Amgen's clinical research program to develop new drugs for the future The focus of the commercial department is to collaborate with healthcare professionals and key stakeholders on the optimal way to use Amgens’ products and to provide them added value services ensuring that we deliver successful treatments to patients.
Amgen Breda collaborating to serve patients around the world.
The biotech revolution of the 1980s changed the game in healthcare. And the world has never looked back. Amgen was born and is one of the original biotech companies.